drugset / Trial / NCT05171530
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
NaSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to study the safety and efficacy of lenvatinib combined with single-agent taxanes therapy in patients with HER2-negative advanced gastric cancer that have failed at the standard first-line therapy.
Timeline
- Start
- 2022-01-05
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Lenvatinib | Small molecule | 4 mg | Oral |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Lenvatinib | Small molecule | 16 mg | Oral |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |